DAIICHI SANKYO CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,636 JPY | +2.20% |
|
+0.09% | +19.73% |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
| Apr. 08 | AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication | MT |
| Sales 2024 * | 1,580B 10.24B | Sales 2025 * | 1,757B 11.38B | Capitalization | 8,698B 56.35B |
|---|---|---|---|---|---|
| Net income 2024 * | 168B 1.09B | Net income 2025 * | 192B 1.25B | EV / Sales 2024 * | 5.15 x |
| Net cash position 2024 * | 556B 3.6B | Net cash position 2025 * | 599B 3.88B | EV / Sales 2025 * | 4.61 x |
| P/E ratio 2024 * |
51.9
x | P/E ratio 2025 * |
45.3
x | Employees | 17,435 |
| Yield 2024 * |
1% | Yield 2025 * |
1.17% | Free-Float | 97.04% |
More Fundamentals
* Assessed data
More news
Latest transcript on Daiichi Sankyo Co., Ltd.
More recommendations
More press releases
More news
| 1 day | +1.94% | ||
| 1 week | -0.17% | ||
| Current month | -3.20% | ||
| 1 month | -5.40% | ||
| 3 months | +6.10% | ||
| 6 months | +29.20% | ||
| Current year | +19.42% |
1 week
4 443.00
4 638.00
1 month
4 443.004 979.00
Current year
3 847.005 173.00
1 year
3 566.005 173.00
3 years
1 981.005 173.00
5 years
1 657.675 173.00
10 years
518.675 173.00
| Managers | Title | Age | Since |
|---|---|---|---|
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
Hiroyuki Okuzawa
PSD | President | 61 | 17-03-31 |
Ken Takeshita
CTO | Chief Tech/Sci/R&D Officer | - | 21-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sawako Nohara
BRD | Director/Board Member | 66 | 19-05-31 |
Kazuaki Kama
BRD | Director/Board Member | 75 | 19-05-31 |
Sunao Manabe
CEO | Chief Executive Officer | 69 | 07-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 25.16% | 15 M€ | +4.25% | ||
| 4.18% | 251 M€ | +13.08% | ||
| 3.32% | 174 M€ | -.--% | - | |
| 3.32% | 51 M€ | -.--% | - | |
| 3.24% | 15 M€ | +11.38% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 4,636 | +2.20% | 5 970 000 |
| 24-04-18 | 4,536 | +2.09% | 3,391,300 |
| 24-04-17 | 4,443 | -2.48% | 2,259,600 |
| 24-04-16 | 4,556 | -0.11% | 2,835,800 |
| 24-04-15 | 4,561 | -1.53% | 2,193,300 |
Delayed Quote Japan Exchange, April 19, 2024 at 01:50 am EDT
More quotes
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,536
JPY
Average target price
5,620
JPY
Spread / Average Target
+23.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.42% | 56.26B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- 4568 Stock
